RecruitingNot Applicable

A New Breath for Malignant Hypertension: Implementation of the HAMA Cohort

France1,200 participantsStarted 2019-09-20

Plain-language summary

This registry aims to provide the first prospective, multicentric database of patients with malignant hypertension. It will allow to assess modern epidemiology of the disease, diversity of current management and care pathway, to deepen our pathophysiological knowledges, to modernize the definition of this form of hypertension and its diagnostic criteria. The network that will emerge will finally lead to the opportunity of setting up therapeutic trials and establishing recommendations based on solid scientific evidence.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Malignant hypertension according to the classic definition (Severe hypertension, above 180/110 associated with severe hypertensive retinopathy) * Severe hypertension (above 180/110) associated with acute damage of 3 target organ due to high blood pressure Exclusion Criteria: * Age \< 18 years old * Patients who cannot freely give their consent, or patients who refuse to participate * Dialysis

What they're measuring

prognosis

Timeframe: 5 years

Trial details

NCT IDNCT03755726

SponsorCentre Hospitalier de PAU

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2034-09-20

View on ClinicalTrials.gov More Malignant Hypertension trials